Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Cadrenal Therapeutics announced that Phase 2 data for its lead asset CAD-1005 has been selected for a late-breaking oral presentation at the upcoming ISTH 2026 Congress in Paris. The presentation will highlight the first-ever randomized, blinded, placebo-controlled trial in Heparin-Induced Thrombocytopenia (HIT), a life-threatening disorder with a peak $2 billion market potential.
Key figures
- Drug Name
- CAD-1005 (formerly VLX-1005)
- Phase Of Trial
- Phase 2
- Peak revenue potential
- $2 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.